Regulatory Approvals

Scholar Rock jumps 12% after FDA approves isembyld for spinal muscular atrophy (SRRK:NASDAQ)

By

Regulatory Approvals — Scholar Rock jumps 12% after FDA approves isembyld for spinal muscular atrophy (SRRK:NASDAQ)  Seeking Alpha

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. September 13, 2026.

By

Related Post

Regulatory Approvals

FDA Approves Isembyld, First SMA Treatment To Target Muscle Loss

Regulatory Approvals

SRRK Shares Surge 12% After FDA Approval of Isembyld for Spinal Muscular Atrophy

Regulatory Approvals

Bayer (XTRA:BAYN) Nears $7.25 Billion Roundup Hearing As FDA Clears New Lung Cancer Drug

Financial News For All

Mergers & Acquisitions

Rocket Lab Stock (RKLB) Opinions on Iridium Merger Proposal

Mergers & Acquisitions

Red Bank Baptist acquires Ridgeview Baptist, creating The Point Church at Brainerd

Mergers & Acquisitions

DASH Ridership Jumps 10%—Now Virginia Is Considering a Regional Merger

Mergers & Acquisitions

Richmond’s Trolley acquires Hampton Roads Taste’s events catering business – The Virginian